Targets › NO
1 program from 1 company in 3 trials: 3 Phase 2; Cardiovascular; next expected readout May 2027.
Open in Phaseline: the race on NO, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Pennsylvania | Potassium Nitrate Nitric oxide donor; increases perfusion and fatty acid oxidation | NO | Phase 2 | Heart Failure With Preserved Ejection Fraction | May 2027 |
Heart Failure With Preserved Ejection Fraction (3)
small molecule (1)
University of Pennsylvania (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.